Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RP 110

Next Previous
X
Search
Drug Profile

RP 110

Alternative Names: RP-110

Latest Information Update: 28 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Remedy Plan Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Neoplastic stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for research development in Cancer in USA
  • 31 Aug 2020 RP 110 is available for licensing as of 31 Aug 2020. https://remedyplan.com/posts/remedy-plan-to-present-at-biotech-showcase-2019-in-san-francisco (Remedy Plan Therapeutics website, August 2020)
  • 31 Aug 2020 Early research in Cancer in USA (unspecified route) before August 2020 (Remedy Plan Therapeutics website, August 2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top